Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163621
2.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620092
3.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369099
4.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172204
5.
Risk as a pattern over time: Delineation of time-dependent risk factors in biological, psychological, and social variables in cancer patients.
Cancer
; 129(21): 3466-3475, 2023 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37470252
6.
Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
Blood
; 138(15): 1331-1344, 2021 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971010
7.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Blood
; 137(25): 3495-3506, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598678
8.
The impact of COVID-19 on cancer care of outpatients with low socioeconomic status.
Int J Cancer
; 151(1): 77-82, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35128650
9.
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Blood
; 134(14): 1132-1143, 2019 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292114
10.
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Nat Chem Biol
; 15(3): 232-240, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30692684
11.
Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells.
Mol Cell
; 49(5): 934-46, 2013 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23395001
12.
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Br J Cancer
; 123(2): 240-251, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32418995
13.
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.
Blood
; 132(18): 1936-1950, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30018080
14.
The Bone's Role in Myeloid Neoplasia.
Int J Mol Sci
; 21(13)2020 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32630305
15.
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Blood
; 130(23): 2499-2503, 2017 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28972014
16.
CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma.
Ann Hematol
; 102(1): 231-234, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399193
17.
The DNA Ligase IV Syndrome R278H Mutation Impairs B Lymphopoiesis via Error-Prone Nonhomologous End-Joining.
J Immunol
; 196(1): 244-55, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26608917
18.
The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells.
Blood
; 124(15): 2391-9, 2014 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25185713
19.
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Haematologica
; 106(8): 2251-2256, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626863
20.
Deep learning for [18F]fluorodeoxyglucose-PET-CT classification in patients with lymphoma: a dual-centre retrospective analysis.
Lancet Digit Health
; 6(2): e114-e125, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135556